Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
UTD2+ tislelizumab+ doxorubicin · 1 trial · 3 indications
time from the first dose to disease progression or any-cause death
| Arm | Type | Description |
|---|---|---|
| UTD2 + tislelizumab + doxorubicin | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| UTD2 + tislelizumab + doxorubicin | DRUG | UTD2: 60 mg/m²/day, orally administered on an empty stomach on Days 1-5 of each cycle (no food 2 hours before and within 1 hour after taking the medication), once daily. Doxorubicin: 75 mg/m²/day, administered by intravenous infusion on Day 1 of each cycle. Doxorubicin is limited to a maximum of 6 cycles. Tislelizumab: 200 mg, administered by intravenous infusion on Day 1 of each cycle. Treatments were repeated every 3 weeks until disease progression (as assessed by the investigator according to RECIST v1.1), intolerable toxicity, withdrawal of informed consent by the participant, loss to follow-up, study termination, death, or when the investigator deemed it necessary to terminate medication or complete maintenance therapy, whichever occurred first. |
Inclusion Criteria: 1. Fully understand the purpose, content, process of the trial and possible adverse reactions, voluntarily participate as a subject, and sign the informed consent form; 2. Age of 18-70 years old (including 18 and 70 years old) at the time of informed consent (ICF) signing, regar...